Nucleic acid nanotheranostics : biomedical applications /
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Amsterdam :
Elsevier,
[2019]
|
| Edition: | First edition. |
| Series: | Micro & nano technologies.
|
| Subjects: | |
| Online Access: | CONNECT |
Table of Contents:
- Front Cover; Nucleic Acid Nanotheranostics: Biomedical Applications; Copyright; Dedication; Contents; Contributors; Preface; Acknowledgments; Chapter 1: Therapeutic Oligonucleotides Against Cancer: Recent Approaches and New Perspectives; 1. Introduction; 2. Mechanisms of Action; 2.1. Antisense Oligodeoxynucleotides (AS-ODNs); 2.2. Small Inhibitory RNAs (siRNAs) and microRNAs (miRNAs); 2.3. Immunostimulatory ODNs (IMOs); 2.4. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 2.5. Aptamers; 3. Delivery; 3.1. Physiological Barriers for TONs Activity; 3.2. Delivery of Naked TONs
- 3.3. Conjugated TONs3.4. Delivery of Encapsulated TONs; 3.4.1. Lipidic Carriers; 3.4.2. Nonlipidic Bionanoparticles; 3.4.3. Polymeric Carriers; 4. Therapeutic Antisense Oligodeoxynucleotides (AS-ODNs) in Cancer; 5. Small Interfering RNA (siRNA); 6. MicroRNA (miRNA); 7. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 8. Aptamers; 9. Conclusions; References; Chapter 2: Small Interfering RNA-Mediated Silencing of the Ribophorin II Gene: Advances in the Treatment of Malignant Bre ... ; 1. Introduction; 2. Biology of RPN2; 2.1. Regulation of Chemoresistance; 2.1.1. Breast Cancer
- 3.2. Toxicity test for RPN2-siRNA4. Conclusion; Acknowledgments; References; Chapter 3: Noncoding RNAs in Cardiovascular Disease; 1. Introduction; 2. Micro-RNAs; 2.1. Biogenesis; 2.2. Mechanism of Action; 3. Long Noncoding RNAs; 3.1. Biogenesis; 3.2. Mechanisms of Action; 3.3. Nuclear lncRNA; 3.3.1. Lnc-RNA-Mediated Methylation; 3.3.2. Direct Heterochromatin Formation; 3.3.3. Transcriptional Interference; 3.3.4. Decoy; 3.3.5. Polymerase II Inhibitors; 3.3.6. Transcriptional Coregulators; 3.3.7. Paraspeckles; 3.3.8. Splicing Modulation; 3.4. Cytoplasmic lncRNAs
- 3.4.1. mRNA Stability Modulation3.4.2. Translational Regulation; 3.4.3. miRNA-lncRNA Interaction; 4. Role of miRNA and lncRNA in Cardiovascular Development and Disease; 4.1. miRNA in Cardiovascular Development; 4.2. miRNA in Cardiovascular Disease; 4.2.1. Fibrosis; 4.2.2. Cardiomyocyte Hypertrophy; 4.2.3. Myocardial Infarction; 4.2.4. Myosin Switching; 4.3. lncRNA in Cardiovascular Development; 4.4. lncRNA in Cardiovascular Disease; 5. ncRNA Therapeutics; 5.1. siRNA and miRNA Therapeutics; 5.1.1. Chemical Modifications to Increase Stability; 5.1.1.1. Backbone Modifications
